EA200700849A1 - Первичная/бустерная противомалярийная вакцина - Google Patents

Первичная/бустерная противомалярийная вакцина

Info

Publication number
EA200700849A1
EA200700849A1 EA200700849A EA200700849A EA200700849A1 EA 200700849 A1 EA200700849 A1 EA 200700849A1 EA 200700849 A EA200700849 A EA 200700849A EA 200700849 A EA200700849 A EA 200700849A EA 200700849 A1 EA200700849 A1 EA 200700849A1
Authority
EA
Eurasian Patent Office
Prior art keywords
primary
malary
vaccine
booster
vaccination regimens
Prior art date
Application number
EA200700849A
Other languages
English (en)
Other versions
EA016648B1 (ru
Inventor
Мария Грация Пау
Яап Гоудсмит
Джозеф Д. Коэн
Патрис М. Дюбуа
В. Энн Стюарт
Доналд Хеппнер
Original Assignee
Круселл Холланд Б.В.
Глаксосмитклайн Байолоджикалс С.А.
Дзе Говермент Оф Дзе Юнайтед Стейтс, Эс Репрезентед Бай Дзе Секретари Оф Дзе Арми, Он Бехаф Оф Дзе Уолтер Рид Арми Инститьют Оф Рисерч
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Круселл Холланд Б.В., Глаксосмитклайн Байолоджикалс С.А., Дзе Говермент Оф Дзе Юнайтед Стейтс, Эс Репрезентед Бай Дзе Секретари Оф Дзе Арми, Он Бехаф Оф Дзе Уолтер Рид Арми Инститьют Оф Рисерч filed Critical Круселл Холланд Б.В.
Publication of EA200700849A1 publication Critical patent/EA200700849A1/ru
Publication of EA016648B1 publication Critical patent/EA016648B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к новым режимам вакцинации, причем специфические режимы первичной/бустерной вакцинации применяются с использованием слабо нейтрализуемых рекомбинантных аденовирусных векторов, содержащих нуклеиновую кислоту, кодирующую антигены Plasmodium falciparum, и вакцин с очищенным рекомбинантным белком, таким как RTS,S, с подходящими адъювантами.
EA200700849A 2004-10-14 2005-10-13 Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии EA016648B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61905604P 2004-10-14 2004-10-14
EP04105035 2004-10-14
PCT/EP2005/055209 WO2006040334A1 (en) 2004-10-14 2005-10-13 Malaria prime/boost vaccines

Publications (2)

Publication Number Publication Date
EA200700849A1 true EA200700849A1 (ru) 2007-10-26
EA016648B1 EA016648B1 (ru) 2012-06-29

Family

ID=34929701

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700849A EA016648B1 (ru) 2004-10-14 2005-10-13 Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии

Country Status (25)

Country Link
US (3) US20080131461A1 (ru)
EP (1) EP1802336B1 (ru)
JP (1) JP5108521B2 (ru)
KR (1) KR20070104881A (ru)
CN (1) CN101068568B (ru)
AT (1) ATE523205T1 (ru)
AU (1) AU2005293572B2 (ru)
BR (1) BRPI0518146A (ru)
CA (1) CA2582455A1 (ru)
CY (1) CY1112749T1 (ru)
DK (1) DK1802336T3 (ru)
EA (1) EA016648B1 (ru)
ES (1) ES2371175T3 (ru)
HK (1) HK1100121A1 (ru)
HR (1) HRP20110786T1 (ru)
IL (2) IL182357A0 (ru)
MA (1) MA29212B1 (ru)
MX (1) MX2007004031A (ru)
NO (1) NO20072470L (ru)
NZ (1) NZ583291A (ru)
PL (1) PL1802336T3 (ru)
PT (1) PT1802336E (ru)
RS (1) RS52187B (ru)
SI (1) SI1802336T1 (ru)
WO (1) WO2006040334A1 (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
WO2003048348A2 (en) * 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
SG156535A1 (en) * 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
WO2006040334A1 (en) * 2004-10-14 2006-04-20 Crucell Holland B.V. Malaria prime/boost vaccines
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US9717788B2 (en) * 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
KR101662571B1 (ko) 2007-11-28 2016-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
CA2706258C (en) 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof
UY31510A1 (es) * 2007-12-06 2009-08-03 Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
CN102016011B (zh) 2008-03-04 2013-12-11 宾夕法尼亚大学托管会 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用
EP2346523A4 (en) * 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
ES2532015T3 (es) * 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
AU2010272685B2 (en) 2009-07-16 2015-02-26 Crucell Holland B.V. Production of polio virus at high titers for vaccine production
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
ES2676196T3 (es) * 2010-12-14 2018-07-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vacunas contra filovirus de adenovirus de serotipo 25 y serotipo 35
EA027236B1 (ru) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
MX357202B (es) 2012-02-16 2018-06-28 Vlp Therapeutics Llc Composicion de particula tipo virus.
CN105473723A (zh) 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
CA2913832C (en) * 2013-06-03 2023-07-04 Vlp Therapeutics, Llc A virus-like particle comprising a malaria antigen and use thereof as a malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10400034B2 (en) 2014-06-26 2019-09-03 Janssen Vaccines & Prevention, B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
WO2016059911A1 (ja) * 2014-10-17 2016-04-21 国立大学法人金沢大学 マラリアワクチン
WO2018183922A1 (en) * 2017-03-30 2018-10-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions for vaccinating against malaria
EP3755369A4 (en) * 2018-02-22 2022-01-19 Turnstone Limited Partnership ONCOLYTIC VIRUSES AS ADJUVANTS
US20220040281A1 (en) * 2018-12-21 2022-02-10 Curevac Ag Rna for malaria vaccines
EP4126028A1 (en) 2020-03-27 2023-02-08 Svenska Vaccinfabriken Produktion AB Compositions and methods for treating and preventing coronaviruses
TW202330575A (zh) 2021-09-29 2023-08-01 瑞典商斯文斯卡疫苗生產股份有限公司 用於治療及預防冠狀病毒之組成物及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
DK0614465T3 (da) * 1991-11-16 1999-09-27 Smithkline Beecham Biolog Hybridprotein mellem CS fra Plasmodium og HBsAg
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
WO2003048348A2 (en) * 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) * 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
SG156535A1 (en) * 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
WO2006040334A1 (en) * 2004-10-14 2006-04-20 Crucell Holland B.V. Malaria prime/boost vaccines
EP1812067B1 (en) * 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof

Also Published As

Publication number Publication date
DK1802336T3 (da) 2011-11-14
NZ583291A (en) 2011-06-30
AU2005293572A1 (en) 2006-04-20
KR20070104881A (ko) 2007-10-29
RS52187B (en) 2012-10-31
MA29212B1 (fr) 2008-02-01
EP1802336B1 (en) 2011-09-07
PT1802336E (pt) 2011-11-15
EA016648B1 (ru) 2012-06-29
AU2005293572B2 (en) 2011-08-04
MX2007004031A (es) 2007-11-08
CN101068568B (zh) 2012-09-26
JP2008516926A (ja) 2008-05-22
WO2006040334A1 (en) 2006-04-20
CA2582455A1 (en) 2006-04-20
CY1112749T1 (el) 2016-02-10
HRP20110786T1 (hr) 2011-12-31
CN101068568A (zh) 2007-11-07
SI1802336T1 (sl) 2012-01-31
IL182357A0 (en) 2007-07-24
NO20072470L (no) 2007-07-16
EP1802336A1 (en) 2007-07-04
BRPI0518146A (pt) 2008-10-28
US20090285879A1 (en) 2009-11-19
PL1802336T3 (pl) 2012-03-30
JP5108521B2 (ja) 2012-12-26
ATE523205T1 (de) 2011-09-15
IL214460A0 (en) 2011-09-27
ES2371175T3 (es) 2011-12-28
US20080131461A1 (en) 2008-06-05
HK1100121A1 (en) 2007-09-07
US20120014994A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
ATE528016T1 (de) Virusähnliche partikel als paramyxovirus- impfstoffe
ATE461710T1 (de) Nipah-virus-impfstoffe
NO20091840L (no) Telomerase-reverstranskriptase-fusjonsprotein, nukleotider som koder for det, og anvendelser derav
MX2021015465A (es) Vacuna para fiebre porcina africana.
MX2019003615A (es) Proteina central y proteina del antigeno de superficie del virus de la hepatitis b y vacunas que comprenden estas.
ATE473238T1 (de) Tuberkulose vaccine mit verbesserter effizienz
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
CY1106433T1 (el) Εμβολια κοκκιδιωσης
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
NO20081541L (no) Ny sjo-lus vaksine
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
EP1535627A4 (en) VACCINE AGAINST RECOMBINANT BCG
WO2013020133A3 (en) Optimized antigens of pneumocystis and use thereof
GB0409559D0 (en) Polypeptide
DK1490100T3 (da) Kombinerede DNA/proteinvaccinepræparater
DK1176192T3 (da) Helicobacter felis-vaccine
WO2008027414A3 (en) Novel p. falciparum vaccine proteins and coding sequences
ATE450546T1 (de) Impfstoffe mit ornithobakterium rhinotracheale- untereinheit
AR027745A1 (es) Acidos nucleicos y proteinas del gen mhp3 de mycoplasma hyopneumoniae y sus usos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU